Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00231348
Status:
COMPLETED
Last Update Posted:
2013-11-13
First Post:
2005-10-03
Brief Title:
Nefazodone in the Treatment of Social Phobia
Sponsor:
Emory University
Organization:
Emory University
Study Overview
Official Title:
Nefazodone in the Treatment of Social Phobia Functional Brain Imaging and Neuroendocrine Correlates
Status:
COMPLETED
Status Verified Date:
2013-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the effectiveness of nefazadone in patients with social anxiety disorder SAD
Detailed Description:
The purpose of this study is to examine the efficacy of the 5HT2 receptor antagonist nefazadone in SAD and to explore regional cerebral blood flow in patients with SAD when confronted with a personal phobic stimulus using positron emission tomography PET Changes in cerebral blood flow were correlated with self-rated anxiety measures
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None